Profile data is unavailable for this security.
About the company
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
- Revenue in USD (TTM)598.00k
- Net income in USD-66.97m
- Incorporated2020
- Employees25.00
- LocationRallybio Corp234 CHURCH STREET, SUITE 1020NEW HAVEN 06510United StatesUSA
- Phone+1 (203) 859-3820
- Fax+1 (302) 636-5454
- Websitehttps://rallybio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| vTv Therapeutics Inc | 1.00m | -20.18m | 41.87m | 16.00 | -- | 2.54 | -- | 41.87 | -6.81 | -6.81 | 0.2701 | 5.47 | 0.029 | -- | 6.54 | 62,500.00 | -73.77 | -111.84 | -170.69 | -- | -- | -- | -2,540.90 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -8.20m | 42.79m | 2.00 | -- | 11.22 | -- | -- | -0.318 | -0.318 | 0.00 | 0.147 | 0.00 | -- | -- | 0.00 | -104.19 | -- | -113.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.09 | -- | -- | -- |
| NextCure Inc | 0.00 | -58.52m | 43.13m | 82.00 | -- | 0.5699 | -- | -- | -2.09 | -2.09 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -50.82 | -22.59 | -54.42 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Hookipa Pharma Inc | 52.16m | -48.60m | 43.28m | 151.00 | -- | 0.5028 | -- | 0.8296 | -5.28 | -5.28 | 4.85 | 7.14 | 0.33 | -- | 309.57 | 345,450.30 | -30.74 | -41.63 | -40.15 | -50.26 | -- | -- | -93.16 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -35.51m | 44.14m | 15.00 | -- | -- | -- | -- | -1.30 | -1.30 | 0.00 | -0.2026 | 0.00 | -- | -- | 0.00 | -356.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Vyne Therapeutics Inc | 493.00k | -33.95m | 44.25m | 10.00 | -- | 0.6965 | -- | 89.77 | -0.8493 | -0.8509 | 0.0124 | 4.31 | 0.0103 | -- | -- | 49,300.00 | -71.12 | -108.41 | -88.91 | -138.57 | -- | -- | -6,885.40 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -24.41m | 45.71m | 14.00 | -- | -- | -- | -- | -0.2843 | -0.2843 | 0.00 | 0.7193 | 0.00 | -- | -- | 0.00 | -68.77 | -218.20 | -118.93 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Rallybio Corp | 598.00k | -66.97m | 46.05m | 25.00 | -- | 0.6503 | -- | 77.01 | -1.59 | -1.59 | 0.0141 | 1.71 | 0.0056 | -- | -- | 13,906.98 | -63.12 | -- | -68.83 | -- | -- | -- | -11,199.50 | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Serina Therapeutics Inc | 179.00k | -18.67m | 46.09m | 4.00 | -- | -- | -- | 257.51 | -9.72 | -9.72 | 0.0403 | -1.86 | 0.0156 | -- | 6.28 | 44,750.00 | -162.58 | -194.46 | -- | -- | 49.72 | 85.80 | -10,438.55 | -2,347.36 | -- | -1.82 | -- | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| LAVA Therapeutics NV | 7.40m | -24.18m | 46.27m | 37.00 | -- | 1.08 | -- | 6.25 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -15.08m | 46.69m | 5.00 | -- | 8.70 | -- | -- | -1.10 | -1.10 | 0.00 | 0.3898 | 0.00 | -- | -- | 0.00 | -112.08 | -- | -146.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Calcimedica Inc | 0.00 | -12.59m | 47.01m | 14.00 | -- | 2.71 | -- | -- | -1.88 | -1.88 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -60.97 | -63.99 | -75.48 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| Xilio Therapeutics Inc | 2.36m | -65.53m | 47.47m | 73.00 | -- | 1.42 | -- | 20.14 | -2.11 | -2.11 | 0.067 | 0.7603 | 0.0259 | -- | -- | 32,287.67 | -71.92 | -- | -102.96 | -- | -- | -- | -2,780.27 | -- | -- | -166.76 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 683.90k | -2.79m | 47.62m | 4.00 | -- | -- | -- | 69.63 | -0.0067 | -0.0067 | 0.0016 | -0.0179 | 0.5379 | -- | 613.36 | 170,975.00 | -219.43 | -276.33 | -- | -- | -- | -- | -407.97 | -1,667.76 | -- | -9.75 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| OncoCyte Corp | 1.02m | -36.80m | 50.51m | 43.00 | -- | 1.77 | -- | 49.37 | -4.26 | -4.26 | 0.1087 | 1.70 | 0.0126 | -- | 1.14 | 23,790.70 | -44.55 | -35.11 | -49.04 | -39.71 | 8.11 | -- | -3,532.75 | -2,373.36 | -- | -154.75 | 0.0212 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Data as of Nov 12 2024. Currency figures normalised to Rallybio Corp's reporting currency: US Dollar USD
23.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Viking Global Investors LPas of 30 Jun 2024 | 4.19m | 10.11% |
| abrdn, Inc.as of 30 Sep 2024 | 1.73m | 4.16% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 847.96k | 2.04% |
| Laurion Capital Management LPas of 30 Jun 2024 | 783.39k | 1.89% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 595.67k | 1.44% |
| Millennium Management LLCas of 30 Jun 2024 | 459.97k | 1.11% |
| Mariner LLCas of 30 Jun 2024 | 405.63k | 0.98% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 340.70k | 0.82% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 296.22k | 0.71% |
| Citadel Advisors LLCas of 30 Jun 2024 | 280.00k | 0.68% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
